Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,013,144
  • Shares Outstanding, K 255,657
  • Annual Sales, $ 3,048 M
  • Annual Income, $ 2,097 M
  • 60-Month Beta 1.65
  • Price/Sales 15.25
  • Price/Cash Flow 57.62
  • Price/Book 10.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.66
  • Number of Estimates 7
  • High Estimate 0.79
  • Low Estimate 0.55
  • Prior Year 0.54
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
173.59 +3.30%
on 03/08/19
193.89 -7.52%
on 03/04/19
-3.75 (-2.05%)
since 02/21/19
3-Month
151.80 +18.12%
on 12/24/18
195.81 -8.43%
on 01/22/19
+22.81 (+14.58%)
since 12/21/18
52-Week
144.07 +24.46%
on 06/06/18
195.81 -8.43%
on 01/22/19
+8.97 (+5.27%)
since 03/21/18

Most Recent Stories

More News
After Yesterday's Decline of 2.45%, Vertex Pharm Offers Investors Better Value

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $181.93 to a high of $185.00. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $184.45...

VRTX : 180.18 (+0.11%)
Vertex Pharm Set to Possibly Rebound After Yesterday's Selloff of 2.45%

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $181.93 to a high of $185.00. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $184.45...

VRTX : 180.18 (+0.11%)
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

Key highlights of the past week are regulatory and pipeline developments.

CELG : 88.95 (+0.66%)
VRTX : 180.18 (+0.11%)
ZFGN : 2.99 (+0.34%)
AMAG : 12.71 (+1.92%)
REGN : 399.61 (-1.45%)
SNY : 45.32 (-0.20%)
CELG vs. VRTX: Which Stock Is the Better Value Option?

CELG vs. VRTX: Which Stock Is the Better Value Option?

CELG : 88.95 (+0.66%)
VRTX : 180.18 (+0.11%)
Vertex Receives Approval for SYMDEKO(R) (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations

---First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function-

VRTX : 180.18 (+0.11%)
Top Research Reports for Amazon, Berkshire Hathaway & Thermo Fisher

Top Research Reports for Amazon, Berkshire Hathaway & Thermo Fisher

PEG : 59.30 (+0.70%)
TMO : 270.14 (+1.70%)
BRK.B : 203.40 (+0.06%)
VRTX : 180.18 (+0.11%)
SQ : 77.09 (+2.43%)
AMZN : 1,803.07 (+0.32%)
Why Is Vertex (VRTX) Down 0.7% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VRTX : 180.18 (+0.11%)
Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.

CNCE : 17.28 (+0.82%)
PTI : 4.33 (-0.69%)
VRTX : 180.18 (+0.11%)
ABBV : 80.28 (-0.19%)
After Yesterday's Decline of 2.26%, Vertex Pharm Offers Investors Better Value

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $183.55 to a high of $186.70. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $186.71...

VRTX : 180.18 (+0.11%)
CORRECTING and REPLACING Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis

---Mean absolute improvement in ppFEV1 of 10.0 percentage points from baseline at week 4 when VX-445 was added in people with two F508del mutations (F/F) already receiving tezacaftor and ivacaftor compared...

VRTX : 180.18 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 183.58
1st Resistance Point 181.78
Last Price 180.18
1st Support Level 178.86
2nd Support Level 177.74

See More

52-Week High 195.81
Last Price 180.18
Fibonacci 61.8% 176.05
Fibonacci 50% 169.94
Fibonacci 38.2% 163.83
52-Week Low 144.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar